Drug Treatment Patterns of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents in Germany: Results from a Large Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Despite a substantial increase in total methylphenidate (MPH) prescriptions in Germany over the last 20 years, and the introduction of modified release MPH (MR MPH) and atomoxetine (ATX), remarkably little is known about treatment patterns of attention- deficit/hyperactivity disorder (ADHD) in individual patients. METHODS: Usage patterns of ADHD drugs in children and adolescents in Germany were analyzed using data from one large German health insurance including >7,200,000 members. Of those, 6210 ADHD patients newly diagnosed in 2005 were followed for a maximum of 4 years. Kaplan-Meier estimates were calculated for onset and discontinuation of ADHD drug treatment. Predictors of time until drug treatment initiation were assessed by Cox regression. RESULTS: During follow-up, 52.0% of ADHD subjects (53.4% of boys, 47.5% of girls) received ADHD drug treatment. The majority of them (91.6%) were started on MPH, with immediate release MPH (IR MPH) being the initial treatment choice in 75.3%. In these subjects, change to drug treatment with MR MPH in the first year occurred in 48% by switch or addition. Significant predictors of drug treatment were behavioral and emotional disorders (HR=1.13; 95% CI 1.03-1.24) and a diagnosis of ADHD with conduct disorder (HR=1.21, 95% CI 1.12-1.32), whereas young age showed a protective effect. After 6, 12, and 24 months of treatment initiation, 22.4%, 43.4%, and 66.3% of treated girls, and 17.8%, 36.1%, and 54.1% of treated boys had discontinued ADHD treatment. CONCLUSION: Drug treatment of ADHD was relatively common in Germany and more frequent in boys than in girls. IR MPH was the predominant treatment choice at treatment initiation. Approximately 20% of treated subjects discontinued drug treatment within the first 6 months, with girls stopping drug treatment earlier than boys. The reasons for early drug discontinuation need to be further explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
European clinical guidelines for hyperkinetic disorder ? first upgrade
Taylor, E., D�pfner, M., Sergeant, J., Asherson, P., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Rothenberger, A., Sonuga-Barke, E., et al. (2004) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-004-1002-x · Cited by 682 · cited 7×
“This is in line with recommendations from the DGKJP and the European Society for Child and Adolescent Psychiatry (ESCAP) (Taylor et al. 2004; Döpfner and Lehmkuhl 2007).”
BackgroundResultSelf-citationContinuity of Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder
Marcus, S. C., Wan, G. J., Kemner, J. E., & Olfson, M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.6.572 · Cited by 163 · cited 5×
“Differently, in the study by Marcus et al. based on Medicaid claims data from California in the United States, a mean treatment duration of 140 days and 103 days was reported for MR MPH and IR MPH, respectively (Marcus et al. 2005).”
MethodResultInfluentialSonuga-Barke, E. J. S., Coghill, D., Wigal, T., DeBacker, M., & Swanson, J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0024 · Cited by 71 · cited 1×
“Although tolerability of treatment with MPH is generally regarded as high, and severe adverse drug reactions are rare (Taylor et al. 2004; Sonuga-Barke et al. 2009), recently concerns have arisen about some rare serious side effects of MPH or other stimulants, including a small number of sudden…”
Background
Cited by
Pelsser, L. M., Frankena, K., Toorman, J., & Rodrigues Pereira, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169277 · Cited by 145
Association of risk of suicide attempts with methylphenidate treatment
Man, K. K. C., Coghill, D., Chan, E. W., Lau, W. C. Y., Hollis, C., Liddle, E., Banaschewski, T., McCarthy, S., Neubert, A., Sayal, K., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2183 · Cited by 140
Self-citationMan, K. K. C., Coghill, D., Chan, E. W., Lau, W. C. Y., Hollis, C., Liddle, E., Banaschewski, T., McCarthy, S., Neubert, A., Sayal, K., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.216 · Cited by 70
Self-citation
Metadata
- Authors
- Garbe, E., Mikolajczyk, R. T., Banaschewski, T., Petermann, U., Petermann, F., Kraut, A. A., & Langner, I.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-12
- Volume
- 22
- Issue
- 6
- Pages
- 452-458
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1998627915
- Cited by
- 67
- References
- 5
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.